GET A PIECE OF AVACEN MEDICAL
Pain is the #1 reason for medical visits, with up to 116 million people in the US and 30% of the global population suffering from chronic pain. AVACEN is helping to solve this problem without the use of drugs or other invasive treatments. Our FDA 510(k) Cleared family of Class II medical devices use a patented thermotherapy platform technology to noninvasively increase blood flow in approximately 10 billion of the body’s smallest blood vessels.
AVACEN recently launched its 3rd-generation family of fully developed, high-demand, unique consumer and practitioner products into the expanding wellness market that grew to $4.4 trillion globally in 2022.
The AVACEN team is backed by successful leaders who have helped the company secure 17 patents and complete 10 pilot studies all supporting billion-dollar market opportunities such as chronic pain, type 2 diabetes, wound healing, fibromyalgia, and opioid addiction.
*Market information provided by (source)
The PITCH
AVACEN® is an innovative, noninvasive medical device that warms your body from the inside out, unlocking positive patient outcomes. AVACEN Medical is a leader in FDA-Cleared pain relief and wellness solutions, and is combating the global epidemic of chronic pain. With up to 116 million sufferers in the U.S. alone, the company offers drug-free, noninvasive over-the-counter pain relief.
THE Problem & OUR Solution
AVACEN Medical has set out to tackle the pervasive problem of pain that plagues millions worldwide. With pain being the primary reason for medical visits, the need for effective and safe solutions is undeniable. Traditional approaches often rely on opioids, which come with significant risks and contribute to the ongoing epidemic.
AVACEN Medical offers a one-of-a-kind alternative. By leveraging a patented method that combines heat and negative pressure to enhance systemic microcirculation, their drug-free, noninvasive, over-the-counter devices provide relief without the side effects of opioids. With over 9,000 devices field tested and sold, and an impressive track record of over 22 million treatments without adverse events, AVACEN Medical is offering a safer alternative to pain management. They're even exploring a new franchise concept called Soothe, empowering licensees to establish their own treatment centers.
The Market & Our Traction
AVACEN Medical is altering the traditional approach to pain management by offering drug-free, noninvasive solutions in response to the opioid crisis and concerns over pharmaceutical side effects. With an astounding 116 million chronic pain sufferers in the U.S., AVACEN Medical addresses the pressing need for alternative treatments. The company's traction is remarkable, with revenue surging from $850K in 2018 to an impressive $4.8 million in 2022. As AVACEN Medical explores new clinical applications in diabetes, fibromyalgia, and wound care, we believe the potential for further revenue growth is substantial.
Supported by 17 patents and counting, AVACEN Medical's state-of-the-art technology is backed by robust intellectual property covering a range of therapeutic uses. The company has earned industry recognition, including being named the Patient Centric Pain Management Technology of the Year in 2022 and securing a spot as a Top 10 Pain Management Device Company. AVACEN Medical's success extends to its international e-commerce initiatives, including Amazon storefronts, and a dedicated sales team of over 250 independent US distributors.
Since its inception, AVACEN Medical has raised $4 million, with an impressive 75% plus of funding directly sourced from customers. With revenues exceeding $20 million to date and consistent cash flow positivity since Q4 2018, the company believes it demonstrates financial stability. Moreover, AVACEN Medical's commitment to innovation is evident through the recent launch of a third-generation technology platform, a new FDA-Cleared cardiac diagnostic, and ongoing development of three additional products for the hospital market. With a distinguished leadership team, global presence, and a track record of success, AVACEN Medical is poised to spearhead the transformative pain management and perioperative market.
Why Invest
Now’s the time to be part of a whole new approach to pain management with AVACEN Medical. With a massive market size and increasing demand for drug-free solutions, AVACEN Medical is uniquely positioned to combat the opioid epidemic and cater to the needs of nearly 116 million chronic pain sufferers in the U.S. alone. The company’s cutting-edge, FDA-Cleared technology has already gained recognition and success, with multiple patents and awards. As AVACEN expands into new clinical indications and international markets, we believe the potential for growth is significant.
Invest in AVACEN Medical today, and join us in transforming the future of pain relief and wellness!
AVACEN (Advanced VAscular Circulation ENhancement) Medical provides FDA Cleared, noninvasive, drug-free over-the-counter pain relief and wellness devices, as well as diagnostics for cardiovascular disease and stress. The company has raised $4 million, sold over 9,000 devices, and has safely completed over 22 million treatments to date.
Anthony Shimkin
CEO, President, Director
Thomas Muehlbauer
Chairman, President, Co-Founder, Product Inventor, and R&D Head
Danielle Forsgren
CMO, Co-Founder, and Board Member
Tom Nauman
Chief Compliance Officer
Rhonda Migliaccio
CFO & VP Administration
James "Jim" Wangler
Board Member & Investor
Donald Miller
Board Member
Fredrick Waid
Board Member
Hamid Khorramian
Board Member/Investor
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives and Bonuses*
Loyalty Bonus | 10% Bonus Shares
As you have previously invested in AVACEN, Inc., you are eligible for additional bonus shares. Receive 10% bonus shares in AVACEN's current offering on StartEngine if you've (i) previously invested in this issuer, (ii) reserved shares formally through the issuer's Test the Waters campaign on StartEngine; or (iii) indicated interest by signing up to receive news regarding the offering on AVACEN's domain.
Note: Loyalty Bonus is awarded via investor email address and investors who qualify for this bonus in multiple ways will receive maximum 10% bonus shares from the Loyalty Bonus.
Combo Perks
Super Early Bird Tier 1
Invest $1,000+ within the first 5 days and receive 5% bonus shares.
Super Early Bird Tier 2
Invest $5,000+ within the first 5 days and receive 10% bonus shares.
Super Early Bird Tier 3
Invest $10,000+ within the first 5 days and receive 15% bonus shares.
Super Early Bird Tier 4
Invest $20,000+ within the first 5 days and receive 20% bonus shares.
Super Early Bird Tier 5
Invest $40,000+ within the first 5 days and receive 25% bonus shares.
Early Bird Tier 1
Invest $1,000+ within the first 10 days and receive 3% bonus shares.
Early Bird Tier 2
Invest $5,000+ within the first 10 days and receive 5% bonus shares.
Early Bird Tier 3
Invest $10,000+ within the first 10 days and receive 10% bonus shares.
Early Bird Tier 4
Invest $20,000+ within the first 10 days and receive 15% bonus shares.
Early Bird Tier 5
Invest $40,000+ within the first 10 days and receive 20% bonus shares.
Amount-Based Perks
$1,000+ | Tier 1
Invest $1,000+ and receive a $1,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device.
$5,000+ | Tier 2
Invest $5,000+ and receive a $2,000 discount (coupon code) applicable to the purchase of any AVACEN Medical HOME XL device.
$10,000+ | Tier 3
Invest $10,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 5% bonus shares.
$20,000+ | Tier 4
Invest $20,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 10% bonus shares.
$40,000+ Tier 5
Invest $40,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 15% bonus shares.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
AVACEN will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owners' Bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owners' Bonus and the Loyalty Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
We will not incur any irregular use of proceeds.
09.23.23
AVACEN's Exciting Presence at RAADfest:
Advancing Wellness and Longevity!
RAADfest is for individuals who are seeking longevity solutions and the future of unlimited health! We were able to connect with entrepreneurs, researchers, and practitioners, learn more about the future of wellness, and share how our devices can contribute to a healthier life.
Members get an extra 10% shares in addition to rewards below!
Earn 10% Bonus Shares
Earn 10% bonus shares in this investment and all eligible investments for an entire year. If you are not already an Owners bonus holder, you can join now, for $275, billed annually.
Tier 1
Invest $1,000+ and receive a $1,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device.
Tier 2
Invest $5,000+ and receive a $2,000 discount (coupon code) applicable to the purchase of any AVACEN Medical HOME XL device.
Tier 3
Invest $10,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 5% bonus shares.
Tier 4
Invest $20,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 10% bonus shares.
Tier 5
Invest $40,000+ and receive a $5,000 discount (coupon code) applicable to the purchase of any AVACEN Medical device PLUS 15% bonus shares.
0/2500
24 days ago
1
0
2 months ago
1
0
3 months ago
0
0
3 months ago
1
0
3 months ago
1
0
3 months ago
1
0
Cancel anytime before 48 hours before a rolling close or the offering end date.
We want you to succeed and get the most out of your money by offering rewards and memberships!
Your info is your info. We take pride in keeping it that way!
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Important Message
IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.
www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.Investment opportunities posted and accessible through the site are of three types:
1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.
Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.
California Investors Only – Do Not Sell My Personal Information(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.
StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.StartEngine Marketplace
The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.
None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.
All investment opportunities are based on indicated interest from sellers and will need to be confirmed.
Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.
StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.
David Amin
9 days ago
0
0